Bacterial Chassis Genome Integration Patents: Leaders & Trends 2026
- 23.0% concentration at the top. The five leading assignees hold 935 of the 4,065 records in scope, but the other 77% is spread across a long tail of single- and few-filing entrants.
- Filings cooled after a 2020 peak. 127 records published in 2020, then a documented -62% swing from 117 in 2021 to 44 in 2024 — the last year the data treats as complete.
- C12N dominates, but the field is multi-class. 93.0% of records carry a C12N microorganism/genetic-engineering class, and nearly half also carry C07K peptide claims, pointing to combined construct-and-product filing strategy.
Filing growth compares 2021 (117 records) with 2024 (44) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,065 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent activity at the intersection of engineered bacterial hosts and the mechanics of getting DNA to sit stably in their genomes — integration sites, homology arms, copy number control, marker excision and recombination efficiency. The search spans C12N15/09 (recombinant DNA technique), C12N1/20 (bacteria), and C12Q1/68 (nucleic-acid based measuring), narrowed to filings that combine host-organism language with integration-mechanics language.
The scope runs from 2015 through the 2026-07-31 data cut-off, covering 4,065 published records. Because publication trails filing by roughly 18 months, activity in the most recent one to two years is undercounted and should not be read as a decline.
Filing trend and technology composition
Two views of the same 4,065-record corpus: the year-by-year filing curve, and the IPC subclasses that make up the technology mix.
A 2020 peak followed by a documented pullback
Publications rose from 82 in 2017 to a peak of 127 in 2020, then declined; the corpus shows a -62% move from 117 records in 2021 to 44 in 2024, the last year treated as complete given the ~18-month publication lag.
C12N anchors the field, C07K and C12P follow
93.0% of records carry a C12N class (microorganisms and genetic engineering). Below that, 48.4% also carry C07K (peptides/proteins), 42.3% carry C12P (fermentation and enzymatic synthesis), and 38.4% carry C12Q (enzyme/DNA measuring) — evidence that most filings pair a host-engineering claim with a product or assay claim rather than filing on the chassis alone.
Shares are the percentage of the 4,065 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bacterial Chassis Genome Integration with Eureka
This page is one run against one query. Ask Eureka your own question about bacterial chassis genome integration and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
3'-sialyllactose-producing engineered bacterium, and construction method and application thereof (WO2025060527A1)
An engineered bacterium producing 3'-sialyllactose carries exogenous UDP-N-acetylglucosamine 2-epimerase (neuC), sialic acid synthase (neuB), N-acetylneuraminate cytidylyltransferase (css) and alpha-2,3-sialyltransferase (ST) genes integrated into its genome or carried on a recombinant plasmid, producing the target sugar without an antibiotic-selection requirement.Filed by Synaura Biotechnology (Shanghai) Co., Ltd., published 2025-03-27.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1992001047A1 | Methods for producing members of specific binding pairs | 8,824 |
| 2 | US5969108A | Methods for producing members of specific binding pairs | 5,319 |
| 3 | WO1992018619A1 | Heterodimeric receptor libraries using phagemids | 4,228 |
| 4 | WO1991017271A1 | Recombinant library screening methods | 3,878 |
| 5 | US5658727A | Heterodimeric receptor libraries using phagemids | 2,726 |
| 6 | WO1994012649A2 | Gene therapy for cystic fibrosis | 2,130 |
| 7 | WO2000060060A2 | Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same | 2,067 |
| 8 | WO1992000377A1 | Glyphosate tolerant plants | 1,837 |
| 9 | EP0142924A2 | Insect resistant plants | 1,578 |
| 10 | US5776760A | Glyphosate tolerant plants | 1,153 |
Citation counts favour older filings simply by virtue of time in circulation; treat them as a measure of influence on the field's foundational methods, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once concentration, timing and classification are read together.
The top of the field is thin relative to its size
Five assignees hold 935 of 4,065 records — a real lead, but one that leaves the large majority of filings distributed across a long tail. That tail is where freedom-to-operate work usually finds the most surprises, since single-filer entities are easy to miss in a leader-focused search.
A cooling curve, not a dead field
The move from 117 records in 2021 to 44 in 2024 is a real, documented drop — but 2025 and 2026 data is still filling in under the standard publication lag, so it is too early to call this a terminal decline rather than a post-peak correction.
Chassis claims rarely stand alone
Nearly all records sit in C12N, but roughly half also carry C07K peptide claims and over 40% carry C12P fermentation claims. Filers are pairing genome-integration mechanics with a specific protein or metabolite output rather than claiming the chassis platform in isolation.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bacterial chassis genome integration, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Novozymes A/S | Novozymes Inc | 55 |
| The Regents of the University of California | The Board of Trustees of the Leland Stanford Junior University | 18 |
| Novo Nordisk Biotech Inc | Novo Nordisk A/S | 17 |
| Corixa Corp | HARLOCKER SUSAN L | 16 |
| Maxygen Holdings Ltd (US) | Maxygen Inc | 16 |
| Corixa Corp | WANG TONGTONG | 15 |
| Corixa Corp | SECRIST HEATHER | 12 |
| Corixa Corp | CARTER DARRICK | 12 |
Only 10 co-assignee pairs appear in the corpus, and the strongest pairings sit inside single corporate groups or university-industry pairs — co-assignment is not a common route to entry in this field.
Who is filing, and where the momentum has gone quiet
The ranking covers 100 companies scored against the full 4,065-record corpus. Momentum data shows several leading assignees at zero filings in the latest year, consistent with the broader post-2021 pullback rather than any single company's retreat.
A clear leader, still active historically
The top-ranked assignee holds 383 records, well ahead of fifth place at 117 — a wide gap that suggests an early and sustained filing programme rather than a recent surge.
A steep drop-off past the top five
Tenth place sits at 58 records, less than half of fifth place's 117 — the field narrows quickly outside the leading names, and most of the ranked 100 hold far smaller counts.
Leading filers show no latest-year activity
Multiple assignees among the historical leaders show zero filings in the latest tracked year, with some recording a -100% year-on-year change. Given the publication lag, this reads as a data-timing effect layered on top of a genuine multi-year slowdown, not proof any one filer has exited.
| Assignee | Recent year | YoY |
|---|---|---|
| Novozymes A/S | 0 | -100% |
| The Scripps Research Institute | 0 | — |
| Corixa Corp | 0 | — |
| Novozymes Inc | 0 | — |
| Monsanto Technology LLC | 0 | -100% |
| Novo Nordisk Biotech Inc | 0 | — |
| Pivot Bio Inc | 0 | -100% |
| Maxygen Holdings Ltd (US) | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the question is who to watch, where to file, or what blocks a given design.
Map claim scope on the leading assignee's portfolio
With 383 records at the top of the ranking, a claim-by-claim read of that portfolio's independent claims is the fastest way to see exactly what is occupied versus assumed to be occupied.
Explore assignee portfolios in EurekaTrack the post-2021 pullback into 2025–2026
The -62% move from 2021 to 2024 is documented; whether it continues depends on filings still emerging under the publication lag. Re-run the trend once another cut-off passes.
Set up trend monitoring in EurekaStress-test the under-claimed sub-areas
Marker-free excision and copy-number control sit outside the densest classes. A prior-art pull scoped narrowly to those terms will show whether the white space is real or just thin data.
Run a white-space search in EurekaCommon questions on this landscape
The ranking covers 100 assignees scored against 4,065 records, with the leading company holding 383 records and a clear gap down to fifth place at 117. The top five combined account for 23.0% of all records in scope, meaning the field has a recognisable leader but is far from a closed field — the remaining 77% is spread across many smaller filers. Anyone doing freedom-to-operate work should check both the leader's core claims and the long tail, since single-filing entities are easy to overlook.
Filings peaked at 127 records in 2020, and the corpus shows a documented -62% change from 117 records in 2021 to 44 in 2024, the last year treated as complete. Because publication typically lags filing by around 18 months, the 2025–2026 figures in the dataset are still filling in and should not be read as confirmation of a continued decline. The honest read is a real post-2020 cooling with an open question about where it settles.
The core class is C12N, covering microorganisms and genetic engineering, present in 93.0% of the 4,065 records. Beneath that, C07K (peptides and proteins) appears in 48.4% of records, C12P (fermentation and enzymatic synthesis) in 42.3%, and C12Q (enzyme/DNA-based measuring) in 38.4%. Because a single record can carry several IPC classes, these shares add up to more than 100% — most filings combine a chassis-engineering claim with a product, assay, or therapeutic claim rather than filing on the host organism alone.
The densest claim space sits in C12N-classed genetic engineering paired with C07K peptide or C12P fermentation output claims. Less crowded ground includes marker-free excision cassette design, single-copy landing-pad site selection, copy-number feedback control circuits, and multi-locus simultaneous integration — these sit adjacent to the core but do not dominate the corpus the way host-organism-plus-product claims do. A narrowly scoped prior-art search on those specific mechanics is the way to confirm whether the gap is real before drafting.
WO2025060527A1, filed by Synaura Biotechnology (Shanghai), covers an engineered bacterium producing 3'-sialyllactose via four exogenous genes — neuC, neuB, css and an alpha-2,3-sialyltransferase — integrated into the host genome or carried on a plasmid, notably without requiring antibiotic selection. It matters most to groups working on sialylated oligosaccharide production strains, particularly anyone relying on antibiotic-marker selection systems for similar pathway integration. Anyone building a comparable production strain should check claim scope around the specific gene combination and the antibiotic-free selection mechanism before finalising a construct design.
Research Bacterial Chassis Genome Integration in depth with Eureka
Go past this page: query the whole bacterial chassis genome integration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.